PDCD1 and neoplasm: Additionally, the IGSF8.06 antibody targeting IGSF8 and NK cell-related receptors, when administered in combination with anti-PD-1 or anti-PD-L1 antibodies, can effectively inhibit immune evasion and therapeutic resistance resulting from tumor cells down-regulating antigen presentation [23].